Clinico-pathological study of locally advanced breast cancer and their hormone receptor analysis
DOI:
https://doi.org/10.18203/2349-2902.isj20203774Keywords:
Locally advanced breast cancer, Estrogen receptors, Progesterone receptorsAbstract
Background: Breast carcinoma is one of the most common malignant tumor of women. Determination of estrogen receptors (ER) and progesterone receptors (PR) status, prior to therapeutic intervention has become standard practice. Survival and response to hormone therapy are most favorable among women who are receptor positive. The aim of this study is to assess the hormone receptor status in locally advanced breast carcinomas and correlate this reactivity pattern with tumor stage, clinical stage and lymph node metastasis. Objective of the study was to co-relate the locally advanced breast cancer and their hormone receptor analysis.
Methods: Patients who visited Department of General Surgery, Hamidia Hospital, Bhopal were assessed clinically, radiologically and histopathologically and then ER and PR study was done, for a total of 50 cases were done.
Results: In our study majority of the cases were locally advanced breast cancer (50%) which may be due to the low socio economic status, late presentation, pain tolerance, illiteracy and availability of the resources. Majority of cases were in postmenopausal, clinical stage 3 and histological grade 2. ER positivity 50% and PR positivity 44% and it was found that hormone receptor positivity was high in locally advanced breast cancers 63.5%.
Conclusions: Hormone receptor analysis should be an integral part of initial workup of carcinoma breast, as the percentage of hormone receptor positivity is increasing in our population in locally advanced breast cancer. So locally advanced breast cancer can be diagnosed at an early stage by screening and conducting breast awareness programs.
References
Malvia S, Bagadi SA, Dubey US, Saxena S. Epidemiology of breast cancer in Indian women. J Clin Oncol. 2017; 13(4):289-95.
Balogun OD, Formenti SC. Locally advanced breast cancer-strategies for developing nations. Front Oncol. 2015;5:89.
Wells CA, Sloane JP, Coleman D, Munt C, Amendoeira I, Apostolikas N, et al . Consistency of staining and reporting of oestrogen receptor immunohistochemistry within the Europian Union: an inter-laboratory study. Virchows Arch. 2004;445:119-28.
Rhodes DJ. Identifying and counseling women at increased risk for breast cancer. Mayo Clin Proc. 2002;77(4):355-61.
Lakhmini KB. Quick score of hormone receptor status of breast carcinoma: correlation with the other clinic-pathological prognostic parameters Ind J Pathol Microbiol. 2009;52(2):159-63.
Marjaneh MM, Shandiz FH, Shamsian S, Zadeh IE, Mashadi IEZ, Moghaddam MRH, et al. Histological grade correlation of HER2/neu over expression, P53 protein accumulation and steroid receptor status with tumor characteristics: an Iranian study of breast cancer patients. Iran J Pub Health. 2008;37(3):19-28.
Dutta CV, Brig GS, Chopra SM, Sahai K, Nema SK. HRs, HER-2/neu and chromosomal aberrations in breast cancer. MJAFI. 2008;64:11-5.
Aziz Z, Iqbal J, Akram M, Anderson BO. Worsened oncologic outcomes for women of lower socio-economic status (SES) treated for locally advanced breast cancer (LABC) in Pakistan. Breast. 2010;19(1):38-43.
Rosen PP, Menendez-Botet CJ, Nisselbaum JS, Urban JA, Mike V, Fracchia A, et al. Pathological review of breast lesions analyzed for estrogen receptor protein1. Cancer Res. 1975;35:3187-94.
Li CI, Daling JR, Malone KE. Incidence of invasive breast cancer by HR status from 1992-1998. J Clin Oncol. 2003:21;28-34.
Priti Lal, Lee K, Chen TB. Correlation of HER-2 status with estrogen and progesterone receptors and histologic features in 3,655 invasive breast carcinomas. Am J Clin Pathol. 2005;123:541-6.
Desai SB, Moonim MT, Gill AK, Punia RS, Naresh KN, et al. HR status of breast cancer in India: a study of 798 tumours. Breast. 2000;9:267-70.
Nisa A, Bhurgri Y, Raza F, Kayani N. Comparison of ER, PR and HER-2/neu (C-erb B 2) reactivity pattern with histologic grade, tumor size and lymph nodestatus in breast cancer. Asian Pacific J Cancer Prev. 2008;9:553-6.
